APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Immunotherapy Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cancer Immunotherapy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025194 pages

Choose your research edition.

Industry ResearchCancer Immunotherapy Drug Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Immunotherapy Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Cancer Immunotherapy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Immunotherapy Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Immunotherapy Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Cancer Immunotherapy Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cancer Immunotherapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Immunotherapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Immunotherapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cancer Immunotherapy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Immunotherapy Drug include Novartis AG, Merck & Co., Inc., Jiangsu Hengrui Medicine Corporation, Pfizer, Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Roche Holding AG, Medimmune, LLC and Juno Pharmaceuticals Pty Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Immunotherapy Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Immunotherapy Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Immunotherapy Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Immunotherapy Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Immunotherapy Drug Segment by Company

Novartis AG

Merck & Co., Inc.

Jiangsu Hengrui Medicine Corporation

Pfizer, Inc.

Bristol-Myers Squibb Company

AstraZeneca plc

Roche Holding AG

Medimmune, LLC

Juno Pharmaceuticals Pty Ltd.

Incyte Corporation

Gilead Sciences, Inc. (Kite Pharma)

Celgene Corporation

bluebird bio, Inc.

BeiGene

Autolus Therapeutics plc

Cancer Immunotherapy Drug Segment by Type

T-Cell Stimulant

PDL-1 Inhibitor

PD-1 Inhibitor

CTLA Antibody

Cancer Immunotherapy Drug Segment by Application

Hospital

Clinic

Others

Cancer Immunotherapy Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Immunotherapy Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Immunotherapy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cancer Immunotherapy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cancer Immunotherapy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cancer Immunotherapy Drug Industry Trends Table 2. Cancer Immunotherapy Drug Industry Drivers Table 3. Cancer Immunotherapy Drug Industry Opportunities and Challenges Table 4. Cancer Immunotherapy Drug Industry Restraints Table 5. Global Cancer Immunotherapy Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cancer Immunotherapy Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cancer Immunotherapy Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Cancer Immunotherapy Drug Sales Market Share by Manufacturers Table 9. Global Cancer Immunotherapy Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Cancer Immunotherapy Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cancer Immunotherapy Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cancer Immunotherapy Drug Manufacturers, Product Type & Application Table 13. Global Cancer Immunotherapy Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Immunotherapy Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of T-Cell Stimulant Table 17. Major Manufacturers of PDL-1 Inhibitor Table 18. Major Manufacturers of PD-1 Inhibitor Table 19. Major Manufacturers of CTLA Antibody Table 20. Global Cancer Immunotherapy Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 22. Global Cancer Immunotherapy Drug Sales by Type (2027-2032) & (k units) Table 23. Global Cancer Immunotherapy Drug Sales Market Share by Type (2021-2026) Table 24. Global Cancer Immunotherapy Drug Sales Market Share by Type (2027-2032) Table 25. Global Cancer Immunotherapy Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Cancer Immunotherapy Drug Revenue by Type (2021-2026) & (k units) Table 27. Global Cancer Immunotherapy Drug Revenue by Type (2027-2032) & (k units) Table 28. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2021-2026) Table 29. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Others Table 33. Global Cancer Immunotherapy Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 35. Global Cancer Immunotherapy Drug Sales by Application (2027-2032) & (k units) Table 36. Global Cancer Immunotherapy Drug Sales Market Share by Application (2021-2026) Table 37. Global Cancer Immunotherapy Drug Sales Market Share by Application (2027-2032) Table 38. Global Cancer Immunotherapy Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Cancer Immunotherapy Drug Revenue by Application (2021-2026) & (k units) Table 40. Global Cancer Immunotherapy Drug Revenue by Application (2027-2032) & (k units) Table 41. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2021-2026) Table 42. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2027-2032) Table 43. Global Cancer Immunotherapy Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Cancer Immunotherapy Drug Sales by Region (2021-2026) & (k units) Table 45. Global Cancer Immunotherapy Drug Sales Market Share by Region (2021-2026) Table 46. Global Cancer Immunotherapy Drug Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Cancer Immunotherapy Drug Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Cancer Immunotherapy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 50. North America Cancer Immunotherapy Drug Sales by Country (2027-2032) & (k units) Table 51. Europe Cancer Immunotherapy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 53. Europe Cancer Immunotherapy Drug Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Cancer Immunotherapy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Cancer Immunotherapy Drug Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Cancer Immunotherapy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Cancer Immunotherapy Drug Sales by Country (2027-2032) & (k units) Table 60. Global Cancer Immunotherapy Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Cancer Immunotherapy Drug Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Cancer Immunotherapy Drug Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Cancer Immunotherapy Drug Revenue Market Share by Region (2021-2026) Table 64. Global Cancer Immunotherapy Drug Revenue Market Share by Region (2027-2032) Table 65. Novartis AG Company Information Table 66. Novartis AG Business Overview Table 67. Novartis AG Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Novartis AG Cancer Immunotherapy Drug Product Portfolio Table 69. Novartis AG Recent Development Table 70. Merck & Co., Inc. Company Information Table 71. Merck & Co., Inc. Business Overview Table 72. Merck & Co., Inc. Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolio Table 74. Merck & Co., Inc. Recent Development Table 75. Jiangsu Hengrui Medicine Corporation Company Information Table 76. Jiangsu Hengrui Medicine Corporation Business Overview Table 77. Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Product Portfolio Table 79. Jiangsu Hengrui Medicine Corporation Recent Development Table 80. Pfizer, Inc. Company Information Table 81. Pfizer, Inc. Business Overview Table 82. Pfizer, Inc. Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolio Table 84. Pfizer, Inc. Recent Development Table 85. Bristol-Myers Squibb Company Company Information Table 86. Bristol-Myers Squibb Company Business Overview Table 87. Bristol-Myers Squibb Company Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Bristol-Myers Squibb Company Cancer Immunotherapy Drug Product Portfolio Table 89. Bristol-Myers Squibb Company Recent Development Table 90. AstraZeneca plc Company Information Table 91. AstraZeneca plc Business Overview Table 92. AstraZeneca plc Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. AstraZeneca plc Cancer Immunotherapy Drug Product Portfolio Table 94. AstraZeneca plc Recent Development Table 95. Roche Holding AG Company Information Table 96. Roche Holding AG Business Overview Table 97. Roche Holding AG Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Roche Holding AG Cancer Immunotherapy Drug Product Portfolio Table 99. Roche Holding AG Recent Development Table 100. Medimmune, LLC Company Information Table 101. Medimmune, LLC Business Overview Table 102. Medimmune, LLC Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Medimmune, LLC Cancer Immunotherapy Drug Product Portfolio Table 104. Medimmune, LLC Recent Development Table 105. Juno Pharmaceuticals Pty Ltd. Company Information Table 106. Juno Pharmaceuticals Pty Ltd. Business Overview Table 107. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolio Table 109. Juno Pharmaceuticals Pty Ltd. Recent Development Table 110. Incyte Corporation Company Information Table 111. Incyte Corporation Business Overview Table 112. Incyte Corporation Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Incyte Corporation Cancer Immunotherapy Drug Product Portfolio Table 114. Incyte Corporation Recent Development Table 115. Gilead Sciences, Inc. (Kite Pharma) Company Information Table 116. Gilead Sciences, Inc. (Kite Pharma) Business Overview Table 117. Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Product Portfolio Table 119. Gilead Sciences, Inc. (Kite Pharma) Recent Development Table 120. Celgene Corporation Company Information Table 121. Celgene Corporation Business Overview Table 122. Celgene Corporation Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Celgene Corporation Cancer Immunotherapy Drug Product Portfolio Table 124. Celgene Corporation Recent Development Table 125. bluebird bio, Inc. Company Information Table 126. bluebird bio, Inc. Business Overview Table 127. bluebird bio, Inc. Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolio Table 129. bluebird bio, Inc. Recent Development Table 130. BeiGene Company Information Table 131. BeiGene Business Overview Table 132. BeiGene Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. BeiGene Cancer Immunotherapy Drug Product Portfolio Table 134. BeiGene Recent Development Table 135. Autolus Therapeutics plc Company Information Table 136. Autolus Therapeutics plc Business Overview Table 137. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolio Table 139. Autolus Therapeutics plc Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Cancer Immunotherapy Drug Distributors List Table 143. Cancer Immunotherapy Drug Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Cancer Immunotherapy Drug Product Image Figure 2. Global Cancer Immunotherapy Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Immunotherapy Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Immunotherapy Drug Sales (2021-2032) & (k units) Figure 5. Global Cancer Immunotherapy Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cancer Immunotherapy Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. T-Cell Stimulant Image Figure 9. PDL-1 Inhibitor Image Figure 10. PD-1 Inhibitor Image Figure 11. CTLA Antibody Image Figure 12. Global Cancer Immunotherapy Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Cancer Immunotherapy Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Cancer Immunotherapy Drug Sales Market Share by Type (2021-2032) Figure 15. Global Cancer Immunotherapy Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Cancer Immunotherapy Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Cancer Immunotherapy Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Cancer Immunotherapy Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Cancer Immunotherapy Drug Sales Market Share by Application (2021-2032) Figure 24. Global Cancer Immunotherapy Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Cancer Immunotherapy Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2021-2032) Figure 27. North America Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Cancer Immunotherapy Drug Sales Market Share by Country (2021-2032) Figure 29. U.S. Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Cancer Immunotherapy Drug Sales Market Share by Country (2021-2032) Figure 34. Germany Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Cancer Immunotherapy Drug Sales Market Share by Country (2021-2032) Figure 41. China Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Cancer Immunotherapy Drug Sales Market Share by Country (2021-2032) Figure 49. Brazil Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Cancer Immunotherapy Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Cancer Immunotherapy Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Cancer Immunotherapy Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Figure 60. North America Cancer Immunotherapy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Figure 62. Europe Cancer Immunotherapy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Cancer Immunotherapy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Cancer Immunotherapy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Cancer Immunotherapy Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Cancer Immunotherapy Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • T-Cell Stimulant
  • PDL-1 Inhibitor
  • PD-1 Inhibitor
  • CTLA Antibody
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • Jiangsu Hengrui Medicine Corporation
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Roche Holding AG
  • Medimmune, LLC
  • Juno Pharmaceuticals Pty Ltd.
  • Incyte Corporation
  • Gilead Sciences, Inc. (Kite Pharma)
  • Celgene Corporation
  • bluebird bio, Inc.
  • BeiGene
  • Autolus Therapeutics plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Immunotherapy Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Immunotherapy Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cancer Immunotherapy Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cancer Immunotherapy Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cancer Immunotherapy Drug Market Dynamics
  1. 2.1 Cancer Immunotherapy Drug Industry Trends
  2. 2.2 Cancer Immunotherapy Drug Industry Drivers
  3. 2.3 Cancer Immunotherapy Drug Industry Opportunities and Challenges
  4. 2.4 Cancer Immunotherapy Drug Industry Restraints
3 Cancer Immunotherapy Drug Market by Manufacturers
  1. 3.1 Global Cancer Immunotherapy Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cancer Immunotherapy Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cancer Immunotherapy Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cancer Immunotherapy Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Immunotherapy Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cancer Immunotherapy Drug Manufacturers, Product Type & Application
  7. 3.7 Global Cancer Immunotherapy Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Immunotherapy Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Immunotherapy Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Immunotherapy Drug Tier 1, Tier 2, and Tier 3
4 Cancer Immunotherapy Drug Market by Type
  1. 4.1 Cancer Immunotherapy Drug Type Introduction
  2. 4.1.1 T-Cell Stimulant
  3. 4.1.2 PDL-1 Inhibitor
  4. 4.1.3 PD-1 Inhibitor
  5. 4.1.4 CTLA Antibody
  6. 4.2 Global Cancer Immunotherapy Drug Sales by Type
  7. 4.2.1 Global Cancer Immunotherapy Drug Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Cancer Immunotherapy Drug Sales by Type (2021-2032)
  9. 4.2.3 Global Cancer Immunotherapy Drug Sales Market Share by Type (2021-2032)
  10. 4.3 Global Cancer Immunotherapy Drug Revenue by Type
  11. 4.3.1 Global Cancer Immunotherapy Drug Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Cancer Immunotherapy Drug Revenue by Type (2021-2032)
  13. 4.3.3 Global Cancer Immunotherapy Drug Revenue Market Share by Type (2021-2032)
5 Cancer Immunotherapy Drug Market by Application
  1. 5.1 Cancer Immunotherapy Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Cancer Immunotherapy Drug Sales by Application
  6. 5.2.1 Global Cancer Immunotherapy Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Immunotherapy Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Cancer Immunotherapy Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Cancer Immunotherapy Drug Revenue by Application
  10. 5.3.1 Global Cancer Immunotherapy Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cancer Immunotherapy Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Cancer Immunotherapy Drug Revenue Market Share by Application (2021-2032)
6 Global Cancer Immunotherapy Drug Sales by Region
  1. 6.1 Global Cancer Immunotherapy Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Immunotherapy Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Immunotherapy Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Cancer Immunotherapy Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Immunotherapy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cancer Immunotherapy Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cancer Immunotherapy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cancer Immunotherapy Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cancer Immunotherapy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cancer Immunotherapy Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cancer Immunotherapy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cancer Immunotherapy Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cancer Immunotherapy Drug Revenue by Region
  1. 7.1 Global Cancer Immunotherapy Drug Revenue by Region
  2. 7.1.1 Global Cancer Immunotherapy Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cancer Immunotherapy Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Cancer Immunotherapy Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Cancer Immunotherapy Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cancer Immunotherapy Drug Revenue (2021-2032)
  8. 7.2.2 North America Cancer Immunotherapy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cancer Immunotherapy Drug Revenue (2021-2032)
  11. 7.3.2 Europe Cancer Immunotherapy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cancer Immunotherapy Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cancer Immunotherapy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cancer Immunotherapy Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cancer Immunotherapy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Cancer Immunotherapy Drug Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Merck & Co., Inc.
  8. 8.2.1 Merck & Co., Inc. Company Information
  9. 8.2.2 Merck & Co., Inc. Business Overview
  10. 8.2.3 Merck & Co., Inc. Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolio
  12. 8.2.5 Merck & Co., Inc. Recent Developments
  13. 8.3 Jiangsu Hengrui Medicine Corporation
  14. 8.3.1 Jiangsu Hengrui Medicine Corporation Company Information
  15. 8.3.2 Jiangsu Hengrui Medicine Corporation Business Overview
  16. 8.3.3 Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Product Portfolio
  18. 8.3.5 Jiangsu Hengrui Medicine Corporation Recent Developments
  19. 8.4 Pfizer, Inc.
  20. 8.4.1 Pfizer, Inc. Company Information
  21. 8.4.2 Pfizer, Inc. Business Overview
  22. 8.4.3 Pfizer, Inc. Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolio
  24. 8.4.5 Pfizer, Inc. Recent Developments
  25. 8.5 Bristol-Myers Squibb Company
  26. 8.5.1 Bristol-Myers Squibb Company Company Information
  27. 8.5.2 Bristol-Myers Squibb Company Business Overview
  28. 8.5.3 Bristol-Myers Squibb Company Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers Squibb Company Cancer Immunotherapy Drug Product Portfolio
  30. 8.5.5 Bristol-Myers Squibb Company Recent Developments
  31. 8.6 AstraZeneca plc
  32. 8.6.1 AstraZeneca plc Company Information
  33. 8.6.2 AstraZeneca plc Business Overview
  34. 8.6.3 AstraZeneca plc Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca plc Cancer Immunotherapy Drug Product Portfolio
  36. 8.6.5 AstraZeneca plc Recent Developments
  37. 8.7 Roche Holding AG
  38. 8.7.1 Roche Holding AG Company Information
  39. 8.7.2 Roche Holding AG Business Overview
  40. 8.7.3 Roche Holding AG Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Holding AG Cancer Immunotherapy Drug Product Portfolio
  42. 8.7.5 Roche Holding AG Recent Developments
  43. 8.8 Medimmune, LLC
  44. 8.8.1 Medimmune, LLC Company Information
  45. 8.8.2 Medimmune, LLC Business Overview
  46. 8.8.3 Medimmune, LLC Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Medimmune, LLC Cancer Immunotherapy Drug Product Portfolio
  48. 8.8.5 Medimmune, LLC Recent Developments
  49. 8.9 Juno Pharmaceuticals Pty Ltd.
  50. 8.9.1 Juno Pharmaceuticals Pty Ltd. Company Information
  51. 8.9.2 Juno Pharmaceuticals Pty Ltd. Business Overview
  52. 8.9.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolio
  54. 8.9.5 Juno Pharmaceuticals Pty Ltd. Recent Developments
  55. 8.10 Incyte Corporation
  56. 8.10.1 Incyte Corporation Company Information
  57. 8.10.2 Incyte Corporation Business Overview
  58. 8.10.3 Incyte Corporation Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Incyte Corporation Cancer Immunotherapy Drug Product Portfolio
  60. 8.10.5 Incyte Corporation Recent Developments
  61. 8.11 Gilead Sciences, Inc. (Kite Pharma)
  62. 8.11.1 Gilead Sciences, Inc. (Kite Pharma) Company Information
  63. 8.11.2 Gilead Sciences, Inc. (Kite Pharma) Business Overview
  64. 8.11.3 Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Product Portfolio
  66. 8.11.5 Gilead Sciences, Inc. (Kite Pharma) Recent Developments
  67. 8.12 Celgene Corporation
  68. 8.12.1 Celgene Corporation Company Information
  69. 8.12.2 Celgene Corporation Business Overview
  70. 8.12.3 Celgene Corporation Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Celgene Corporation Cancer Immunotherapy Drug Product Portfolio
  72. 8.12.5 Celgene Corporation Recent Developments
  73. 8.13 bluebird bio, Inc.
  74. 8.13.1 bluebird bio, Inc. Company Information
  75. 8.13.2 bluebird bio, Inc. Business Overview
  76. 8.13.3 bluebird bio, Inc. Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolio
  78. 8.13.5 bluebird bio, Inc. Recent Developments
  79. 8.14 BeiGene
  80. 8.14.1 BeiGene Company Information
  81. 8.14.2 BeiGene Business Overview
  82. 8.14.3 BeiGene Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 BeiGene Cancer Immunotherapy Drug Product Portfolio
  84. 8.14.5 BeiGene Recent Developments
  85. 8.15 Autolus Therapeutics plc
  86. 8.15.1 Autolus Therapeutics plc Company Information
  87. 8.15.2 Autolus Therapeutics plc Business Overview
  88. 8.15.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolio
  90. 8.15.5 Autolus Therapeutics plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Immunotherapy Drug Value Chain Analysis
  2. 9.1.1 Cancer Immunotherapy Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Immunotherapy Drug Production Mode & Process
  6. 9.2 Cancer Immunotherapy Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Immunotherapy Drug Distributors
  9. 9.2.3 Cancer Immunotherapy Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst